Function of SLC7A7 in T-Cell Acute Lymphoblastic Leukemia

Ji, Xiaohui; Yang, Xiaoyun; Wang, Nan; Kang, Meiyun; Wang, Yaping; Rong, Liucheng; Fang, Yongjun; Xue, Yue

doi:10.1159/000491899

Cited by 10 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Y+LAT1 protein, encoded by the SLC7A7 gene, forms the cationic amino acid transport system y+L, which transports cationic and large neutral amino acids from the cell to the extracellular space. Knockdown of SLC7A7 increased the cell apoptosis but decreased the G1 phase and cellular invasion in T-cell acute lymphoblastic leukemia [30].The common single nucleotide polymorphism (rs12436190) in SLC7A7 increases the risk of glioma in Chinese population [31]. Our study demonstrated that high SLC7A7 expression was associated with decreased OS and RFS in glioma patients.…”

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

The Solute Carrier Family 7 Genes Are Potential Diagnostic and Prognostic Biomarkers in Lower Grade Glioma

Ren

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The solute carrier (SLC) 7 family genes are a group of cationic amino acid/glycoprotein transporters and of importance to the maintenance of amino acid nutrition and survival of tumour cells. This study was to investigate the diagnostic values of SLC7 family genes and their associations with overall survival (OS) and relapse-free survival (RFS) in Lower grade glioma (LGG). Methods: SLC7 family gene expression and clinical data were retrieved from The Cancer Genome Atlas and the Chinese Glioma Genome Atlas database. The expression difference of SLC7 family genes was compared between 523 LGG and 1141 normal brain tissues. The associations between gene expression, clinicopathologic factors, patients’ OS and RFS were analysed by various statistical methods in the two datasets. Results: As compared to normal brain tissues, SLC7A10 expression was significantly down-regulated, while SLC7A5, SLC7A7 expression was significantly up-regulated in LGG tissues. Multivariate analysis and validation analysis confirmed that increased SLC7A7 expression was associated with increased mortality (P≤0.001, Odd ratio [OR]:2.66, 95% Confidence interval [CI]: 1.56–4.6). While, increased SLC7A4 and SLC7A14 expression was associated with reduced mortality (P=0.02, OR:0.38, 95% CI: 0.16–0.81; P≤0.001, OR:0.38, 95% CI: 0.21–0.67; respectively). Increased SLC7A11 expression was associated with decreased RFS (P=0.01, OR:0.61, 95% CI: 0.43–0.88). Conclusion: SLC7A5, SLC7A7, SLC7A10 might serve as diagnostic biomarkers in LGG. High SLC7A4, SLC7A7 and SLC7A14 expression is significantly associated with OS. SLC7 family gene expression represents a potentially diagnostic and prognostic biomarker to predict survival in LGG.

show abstract

Section: Discussionmentioning

confidence: 61%

“…SLC7A7 may also become promising druggable targets for LGG patients. Take SLC7A7 for example, inhibition of SLC7A7 expression increased the cell apoptosis, decreased the G1 phase and inhibited cell invasion in T-cell acute lymphoblastic leukemia [30].…”

Section: Discussionmentioning

confidence: 99%

The Solute Carrier Family 7 Genes Are Potential Diagnostic and Prognostic Biomarkers in Lower Grade Glioma

Ren

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…SLC7A5 might cause different effects in different cell lines since it was reported that after knockdown of SLC7A5, cell cycle progression had been detected to be arrested at G1 phase in oral cancer [25], gastric cancer [26], and esophageal cancer [24,27]. Moreover, the cell number of G2 phase showed a signi cant increase while SLC7A5 was knockdown in T-cell acute lymphoblastic leukemia [48]. In the results of FACS, cell cycle was arrested in G1 phase after SLC7A5 knockdown obviously.…”

Section: Discussionmentioning

confidence: 97%

SLC7A5 Promotes Colorectal Cancer Progression by Regulating Cell Cycle and Migration

Tang

Zhang

Cheng

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Solute carrier family 7 member 5 (SLC7A5) was identified highly expressed and as a key participant in various tumor development; however, the role it played in colorectal cancer remains unclear. Methods and Results: In the current study, the expression of SLC7A5 were systematically mined in public databases and validated by real-time PCR in colon cancer and normal tissues. And then, the co-expression and pathway analysis got from public database, which indicated the potential influence of SLC7A5 for the etiology of colorectal cancer, were evaluated in the colon cancer cell lines by loss of SLC7A5 function experiment, flow cytometry, western blot, and wound healing assay. The results showed that the mRNA expression of SLC7A5 was significantly higher in colorectal cancer tissues than that in the non-tumor controls for GEO and TCGA datasets as well as 40 pairs of Xiangya clinical samples. The functional enrichment analysis based on public database showed that the pathways enriched most were cell cycle and epithelial-to-mesenchymal transition (EMT), and Cyclin D1 (CCND1) were the only gene that had a significant positive correlation with SLC7A5. Loss of SLC7A5 function in colon cancer cell lines could arrest cell cycle at G1 phase by down-regulating CCND1 and CDK2 protein expression, and may reduce cell migration by reversing EMT though upregulation of E-Cadherin and downregulation of zonula occludens-1. Conclusion: SLC7A5 is likely associated with the progression of colon cancer.

show abstract

“…In NSCLC, SLC7A7 is a prognostic biomarker correlated with immune infiltrates ( Dai et al, 2021 ). For T cell acute lymphoblastic leukemia, SLC7A7 inhibits cell apoptosis and promotes cell migration and invasion ( Ji et al, 2018 ). Downregulation of SLC7A7 triggers an inflammatory phenotype in human macrophages and airway epithelial cells ( Rotoli et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer

Liu

Shang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

BackgroundsThe high morbidity and mortality of lung cancer are serious public health problems. The prognosis of lung cancer and whether to apply immune checkpoint blockade (ICB) are currently urgent problems to be solved.MethodsUsing R software, we performed Kaplan–Meier (K-M) analysis, Cox regression analysis, functional enrichment analysis, Spearman correlation analysis, and the single-sample gene set enrichment analysis.ResultsOn the Tumor IMmune Estimation Resource (TIMER2.0) website, we calculated the abundance of tumor-infiltrating immune cells (TIICs) of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. B cell and myeloid dendritic cell (DC1) were independent prognostic factors for LUAD and LUSC patients, respectively. Enrichment analysis confirmed that genes highly related to B cell or DC1 were closely related to the immune activation of lung cancer patients. In terms of adaptive immune resistance markers, CD8A, CD8B, immunomodulators (immunostimulants, major histocompatibility complex, receptors, and chemokines), immune-related pathways, tumor microenvironment score, and TIICs, high B cell/DC1 infiltration tissue was inflamed and immune-activated and might benefit more from the ICB. Genes most related to B cell [CD19, toll-like receptor 10 (TLR10), and Fc receptor-like A (FCRLA)] and DC1 (ITGB2, LAPTM5, and SLC7A7) partially clarified the roles of B cell/DC1 in predicting ICB efficacy. Among the 186 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, there were three and four KEGG pathways, which partially explained the molecular mechanisms by which B cell and DC1 simultaneously predicted the prognosis and efficacy of immunotherapy, respectively. Among five immune subtypes, the abundance of B cell/DC1 and expression of six hub genes were higher in immune C2, C3, and C6.ConclusionB cell and DC1 could predict the prognosis and ICB efficacy of LUAD and LUSC patients, respectively. The six hub genes and seven KEGG pathways might be novel immunotherapy targets. Immune C2, C3, and C6 subtypes of lung cancer patients might benefit more from ICB therapy.

show abstract

Function of SLC7A7 in T-Cell Acute Lymphoblastic Leukemia

Cited by 10 publications

References 31 publications

The Solute Carrier Family 7 Genes Are Potential Diagnostic and Prognostic Biomarkers in Lower Grade Glioma

The Solute Carrier Family 7 Genes Are Potential Diagnostic and Prognostic Biomarkers in Lower Grade Glioma

SLC7A5 Promotes Colorectal Cancer Progression by Regulating Cell Cycle and Migration

The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer

Contact Info

Product

Resources

About